%20(1).svg)
Serán Featured Guest in Biospace Denatured Podcast: The Unintended Consequences of Small Molecules
Continuing on from the previous episode of Biospace's Denatured "The Gap is Where the Pain Is", this episode focuses on a healthy discussion regarding the IRA, particularly the unintended consequences to small molecule development within the industry and for patients.
Serán CEO Dan Smithey, alongside industry thought leaders, focus in on small molecule development, considerations and potential reasoning behind negotiated patent timelines for small vs. large molecules, and next steps toward a solution to equalize the negotiation timeline.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Ali Pashazadeh, CEO,Treehill Partners
Dan Smithey, President, CEO and Co-founder, Serán BioScience
Matthew Price, COO and Co-founder, Promontory Therapeutics
Peter Rubin, Executive Director, No Patient Left Behind
Rob Williamson, President and COO, Triumvira Immunologics
Listen on Spotify. Approximately 25-minute listening time.
About Serán
Serán BioScience, LLC, is a science-driven drug development partner, recognized as a world leader in drug development. Utilizing a foundation of physical and chemical science, Serán designs robust formulations and engineered solutions to some of the industry's toughest drug product problems. Our experience and background cover a wide range of pharmaceutical manufacturing concepts bringing our world-class expertise to you and your drug product. Serán’s team has decades of experience developing complex drug molecules into enabling medicines. With every addition to our team, we further our commitment to our clients’ success. From preclinical to GMP and beyond, Serán is here to support you and your drug product every step of the way.
For more information, email us at [email protected].
Contact
Brinette Holdren
Director of Marketing
Serán BioScience, LLC
63047 Layton Ave,
Bend, OR 97701 USA
Phone: (541)-237-8501
www.seranbio.com
.svg)